AR090726A1 - VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS - Google Patents

VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS

Info

Publication number
AR090726A1
AR090726A1 ARP130101267A ARP130101267A AR090726A1 AR 090726 A1 AR090726 A1 AR 090726A1 AR P130101267 A ARP130101267 A AR P130101267A AR P130101267 A ARP130101267 A AR P130101267A AR 090726 A1 AR090726 A1 AR 090726A1
Authority
AR
Argentina
Prior art keywords
vaccines
dogs
procedures
disease
immunogenic composition
Prior art date
Application number
ARP130101267A
Other languages
Spanish (es)
Inventor
M Lohse Robert
F M Meeus Patrick
J Millership Jason
Xu Zach
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of AR090726A1 publication Critical patent/AR090726A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición inmunógena que comprende un fragmento antigénico de proteína OspA de Borrelia burgdorferi y una proteína quimérica que contiene fragmentos antigénicos de diferentes filotipos de proteína OspC de Borrelia burgdorferi. También vacunas que incorporan la composición inmunógena de la presente, así como procedimientos para prevenir la enfermedad de Lyme en perros y/o proteger perros de la enfermedad de Lyme usando las vacunas.An immunogenic composition comprising an antigenic fragment of Borrelia burgdorferi OspA protein and a chimeric protein containing antigenic fragments of different OspC protein filotypes of Borrelia burgdorferi. Also vaccines that incorporate the immunogenic composition herein, as well as procedures to prevent Lyme disease in dogs and / or protect dogs from Lyme disease using vaccines.

ARP130101267A 2012-04-18 2013-04-17 VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS AR090726A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18

Publications (1)

Publication Number Publication Date
AR090726A1 true AR090726A1 (en) 2014-12-03

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101267A AR090726A1 (en) 2012-04-18 2013-04-17 VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS

Country Status (10)

Country Link
EP (1) EP2838555A2 (en)
JP (1) JP2015514776A (en)
CN (1) CN104379164A (en)
AR (1) AR090726A1 (en)
AU (1) AU2013249229A1 (en)
BR (1) BR112014025740A2 (en)
CA (1) CA2870179C (en)
EA (1) EA201491668A1 (en)
UY (1) UY34745A (en)
WO (1) WO2013158818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204404A4 (en) 2014-10-08 2018-06-06 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
EP3720489A1 (en) * 2017-12-04 2020-10-14 Intervet International B.V. Canine lyme disease vaccine
CN110483624B (en) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 Borrelia garinii OspA protein C-terminal peptide segment and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
DK0598816T3 (en) * 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A proteins from Borrelia Burgdorferi subgroups, which encode genes and vaccines
WO2000006745A1 (en) 1998-07-31 2000-02-10 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
EP2283031B1 (en) 2008-05-02 2017-04-12 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
EP2630162A4 (en) * 2010-10-20 2014-04-30 Univ Virginia Commonwealth Polyvalent chimeric ospc vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
WO2013158818A2 (en) 2013-10-24
AU2013249229A1 (en) 2014-10-23
CA2870179A1 (en) 2013-10-24
JP2015514776A (en) 2015-05-21
EA201491668A1 (en) 2015-08-31
CN104379164A (en) 2015-02-25
BR112014025740A2 (en) 2017-07-04
UY34745A (en) 2013-11-29
WO2013158818A3 (en) 2014-04-17
CA2870179C (en) 2018-09-04
EP2838555A2 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
IL267997A (en) Compositions, formulations and methods for treating ocular diseases
MX2012013264A (en) Ospa chimeras and use thereof in vaccines.
BR112012005225B8 (en) USE OF AN ACTRIIB-FC FUSION PROTEIN FOR THE TREATMENT OF A DISORDER RELATED TO BONE OR ASSOCIATED WITH MUSCLE LOSS DUE TO FAULT MUSCLE GROWTH
CO7151522A2 (en) Interleukin-10 fusion proteins and uses thereof
CO7160093A2 (en) Anti-egfr antibodies and uses thereof
IL257057A (en) Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine
MX2015011199A (en) Csf1 therapeutics.
BR112014023937A2 (en) pharmaceutical composition, pharmaceutical combination and treatment method
AR090465A1 (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO
DOP2013000235A (en) FUSION PROTEINS AND COMBINATION VACCINES THAT INCLUDE PROTEIN E AND PILINA A OF HAEMOPHILUS INFLUENZAE.
MX2019003004A (en) Compositions for immunising against staphylococcus aerus.
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
BR112016013109A2 (en) anti-siglec-8 antibodies and methods of use
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.
IN2015DN02729A (en)
BR112018013756A2 (en) surgical sutures to enlarge the skin
TR201910866T4 (en) Combined preparations for cancer treatment.
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR094851A1 (en) BICYCLIC COMPOUNDS AS S1P₁ AGONISTS
BR112015016033A8 (en) pharmaceutical compositions for treating bacterial infections, and their uses
BR112015001843A2 (en) medical device, biodegradable matrix composition and method for treating a patient.
CL2015003563A1 (en) Marker for acid sphingomyelinase disorders and their uses.
AR090726A1 (en) VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure